All In Biotech

Drug Trial Radar · NCT03737110

Study to Assess the Efficacy and Safety of Rilonacept Treatment in Participants With Recurrent Pericarditis

Phase 3, Double-Blind, Placebo-Controlled, Randomized Withdrawal Study With Open-label Extension, to Assess the Efficacy and Safety of Rilonacept Treatment in Subjects With Recurrent Pericarditis

Last checked: Nov 20, 2026Latest source record: Sep 6, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

86

Actual

Start

Jan 7, 2019

Primary completion

May 29, 2020

Study completion Jun 30, 2022

Sponsor

Sponsor type
Industry
First posted
Nov 9, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study was to assess the efficacy of rilonacept treatment in participants with recurrent pericarditis.

Conditions

  • Recurrent Pericarditis

Interventions

  • RilonaceptDrug

    Rilonacept 320 mg (or 4.4 mg/kg in pediatric participants ≥12 and \<18 years old) SC , followed by 160 mg (or 2.2 mg/kg in pediatric participants ≥12 and \<18 years old) injections once weekly

  • PlaceboDrug

    Placebo SC injections once weekly

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to Pericarditis Recurrence in the RW PeriodTime frame: RW Period (mean 24.8 weeks)

Locations

21 sites in 4 countries. Site status is shown where the registry gives one.

  • Cedars-Sinai Medical Institute

    Los Angeles, California

  • Arthritis and Rheumatology of Georgia

    Atlanta, Georgia

  • The Loretto Hospital

    Chicago, Illinois

  • Minneapolis Heart Institute Foundation

    Minneapolis, Minnesota

  • Mayo Clinic - PPDS

    Rochester, Minnesota

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio

  • Cleveland Clinic

    Cleveland, Ohio

  • Cardiology Consultants of Philadelphia

    Yardley, Pennsylvania

  • Intermountain Healthcare

    Murray, Utah

  • University Of Vermont Medical Center

    Burlington, Vermont

  • Virginia Commonwealth University

    Richmond, Virginia

  • Swedish Medical Center

    Seattle, Washington

  • HeartCare Partners Clinical Research Unit

    Milton, Queensland, Australia

  • GenesisCare - Cardiology Research

    Doncaster East, Victoria, Australia

  • Bnai Zion Medical Center

    Haifa, Israel

  • Shaare Zedek Medical Center

    Jerusalem, Israel

  • Galilee Medical Center

    Nahariya, Israel

  • Sheba Medical Center at Tel-Hashomer

    Ramat Gan, Israel

  • Ospedale Pediatrico Bambino Gesù

    Rome, Lazio, Italy

  • ASST Fatebenefratelli Sacco - Ospedale Fatebenefratelli e Oftalmico

    Milan, Lombardy, Italy

  • Azienda Ospedaliera Città della Salute e della Scienza di Torino

    Turin, Piedmont, Italy

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.